Every Form 4 that Neurocrine Biosciences Inc (NBIX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NBIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NBIX filings page.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Scientific Officer Jude Onyia acquired 3,587 shares of Common Stock on September 11, 2026 from the vesting of previously granted performance restricted stock units (PRSUs) after a performance metric was certified as achieved.
On the same date, 1,936 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements related to that vesting at a reference price of $156.22 per share; the company states that no shares were sold, and no Rule 10b5-1 trading plan is reported.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Legal Officer Darin Lippoldt received 4,483 shares of common stock on September 11, 2026 through the vesting of previously granted performance restricted stock units (PRSUs) after achievement of a specified performance metric was certified.
On the same date, 2,419 shares were withheld by the company at $156.22 per share to satisfy tax withholding requirements related to the PRSU vesting, and the disclosure states that no shares were sold. No Rule 10b5-1 trading plan is reported.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Medical Officer Sanjay Chandru Keswani had performance restricted stock units vest upon achievement of a certified performance metric on September 11, 2026, resulting in an acquisition of 3,914 shares of common stock. On the same date, 2,112 shares were withheld by the company at $156.22 per share to satisfy tax withholding requirements on the vesting; the company states that no shares were sold in the market.
NEUROCRINE BIOSCIENCES INC (NBIX) director Kevin Charles Gorman reported equity compensation activity on September 11, 2026. He acquired 14,343 shares of common stock at no cost upon vesting of previously granted performance restricted stock units after a performance metric was certified as achieved.
On the same date, 7,839 shares of common stock were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements related to the PRSU vesting at a reference price of $156.22 per share; no shares were sold into the market. Following these transactions, 517,797 outstanding shares are held by the Gorman and Blais Family Trust, over which Dr. Gorman has voting and investment power.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Executive Officer and director Kyle Gano had performance-based equity awards vest on September 11, 2026, resulting in acquisitions of 6,275 and 1,842 shares of common stock at no cost upon certification of a performance metric. On the same date, 3,386 and 994 shares were withheld by the company at $156.22 per share to satisfy tax withholding obligations on the vesting of these PRSUs; the filing states that no shares were sold and no Rule 10b5-1 trading plan is reported.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Regulatory Officer Ingrid Delaet received a grant of 4,483 shares of common stock on September 11, 2026 upon certification of a performance metric tied to previously awarded performance restricted stock units (PRSUs). On the same date, 2,419 shares were withheld by the company at a price of $156.22 per share to satisfy tax withholding requirements on the PRSU vesting, and the filing specifies that no shares were sold. No Rule 10b5-1 trading plan was reported for these transactions.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Human Resources Officer Julie Cooke received a grant/award of 3,587 shares of Common Stock on September 11, 2026 upon certification of a performance metric for previously granted performance restricted stock units (PRSUs). On the same date, 1,936 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on the PRSU vesting at a value of $156.22 per share; no shares were sold in the market. The filing notes that 21,985 of the reported shares are held by the Cooke Family Trust of 2004, over which Julie Cooke has voting and investment power, and no Rule 10b5-1 trading plan is reported.
Neurocrine Biosciences, Inc. (NBIX) reported insider equity activity by Chief Corp. Affairs Officer David W. Boyer. On September 11, 2026, 3,587 shares of common stock were acquired at no cost upon vesting of previously granted performance restricted stock units after a performance metric was certified. On the same date, 1,936 shares were withheld by the company to satisfy tax withholding requirements on the PRSU vesting, and no shares were sold in that transaction. On September 14, 2026, 826 shares were sold in the open market at a weighted average price of $157.4462 per share under a Rule 10b5-1 trading plan adopted on February 23, 2026.
Neurocrine Biosciences Inc. (NBIX) reported that Chief Commercial Officer Eric Benevich received a grant/award acquisition of 6,275 shares of common stock on September 11, 2026 upon certification of a performance metric under previously granted PRSUs. On the same date, the company withheld 3,386 shares at $156.22 per share to satisfy tax withholding requirements on the vesting; the filing states that no shares were sold and no Rule 10b5-1 trading plan is reported.
Neurocrine Biosciences Inc (NBIX) Chief Financial Officer Matt Abernethy reported a mix of equity award vesting, tax withholding, and open-market sales. On September 11, 2026, 5,020 shares of common stock were acquired upon vesting of performance restricted stock units after a performance metric was certified; on the same date, 2,709 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements, with no shares sold in that transaction. On September 14, 2026, he sold 2,311 shares of common stock in transactions effected by a broker at a weighted average price of $157.1981 per share, under a Rule 10b5-1 trading plan, with individual sale prices ranging from $157.05 to $157.43 per share.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Commercial Officer Eric Benevich exercised employee stock options and sold a portion of the resulting shares. On September 9, 2026, he exercised options for 3,194 shares of common stock at an exercise price of $43.24 per share, and on the same date sold 2,154 shares of common stock at $154.61 per share. The options had been granted on February 6, 2017 and were scheduled to expire on February 6, 2027. The sale was effected by a broker under a Rule 10b5-1 trading plan adopted by Mr. Benevich on June 10, 2026, and company policy restricts him from amending such plans after adoption. A separate footnote states that his reported holdings include 178 shares acquired through the company’s 2018 Employee Stock Purchase Plan.
NEUROCRINE BIOSCIENCES INC (NBIX) director Stephen A. Sherwin reported a disposition of company shares through a bona fide gift of 1,000 shares of Common Stock effective September 2, 2026. According to the filing, this was a gift/charitable contribution, not a market transaction, and no value was received for the shares.
Following this charitable transfer, Sherwin directly holds 14,860 shares of Neurocrine Biosciences Common Stock. No Rule 10b5-1 trading plan is reported in connection with this transaction.
NEUROCRINE BIOSCIENCES INC Chief Scientific Officer Jude Onyia reported a bona fide gift of 2,409 shares of common stock effective August 4, 2026. No value was received and it was not a market transaction. Following the gift, Onyia directly holds 20,996 shares of common stock.
Neurocrine Biosciences director Leslie V. Norwalk reported trades in company stock. On July 28, 2026, she sold 1,250 common shares at a weighted-average price of $182.006 per share in multiple open-market transactions executed pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025, with issuer policy restricting later plan modifications. On July 29, 2026, she exercised Non-Qualified Stock Options to acquire 842 common shares at an exercise price of $139.43 per share, leaving 2,140 options from that grant outstanding, which expire on May 22, 2034.
Neurocrine Biosciences Inc. Chief Regulatory Officer Ingrid Delaet reported an exercise-and-sale sequence in company stock. She exercised options to acquire 4,367 shares of common stock at $106.02 per share and, on the same date, sold 4,367 shares in open-market transactions at an average price of $181.02 per share. Following these transactions, she held 20,592 shares of common stock directly in one non-derivative holding and 16,225 shares in another reported line. The sale was carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, and the exercised options were originally granted in 2021 with a vesting schedule through 2025.
Neurocrine Biosciences Inc. Chief Legal Officer Darin Lippoldt reported an open-market sale of 10,000 shares of common stock at a weighted average price of $179.6014 per share. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025, with individual trade prices ranging from $179.50 to $179.80.
On the same date, Lippoldt also exercised non-qualified stock options covering 10,000 shares of common stock at an exercise price of $81.49 per share, reducing the reported option balance to 4,965 options on this grant. These options were granted on February 5, 2018, vested in 48 equal monthly installments beginning March 5, 2018, and are scheduled to expire on February 5, 2028.
Neurocrine Biosciences Chief Regulatory Officer Ingrid Delaet reported a series of option exercises and related stock sales in early July. She exercised stock options covering 14,571 shares of common stock at an exercise price of $103.52 per share, then sold an equal number of shares in open-market transactions at weighted average prices around $178.55–$178.72 per share.
The transactions on July 7–9, 2026 were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following these trades, Delaet directly owns 16,225 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 10,000 shares of common stock and sold 10,000 shares in open-market transactions. The options had an exercise price of $81.49 per share, while the reported sales occurred around $169.57–$170.91 per share on June 26 and June 29, 2026.
The filing shows this as an exercise-and-sell pattern, converting option value into cash rather than increasing net share ownership. After these transactions, Lippoldt directly holds 54,729 shares of Neurocrine Biosciences common stock and retains additional non-qualified stock options. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025.
NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin reported an exercise-and-sell Form 4 transaction in company common stock. On June 5, 2026, he exercised non-qualified stock options for a total of 25,000 shares of common stock at exercise prices of $79.79 and $53.64 per share. On the same date, he conducted open-market sales totaling 25,000 shares at weighted average prices ranging from about $163.81 to $167.31 per share, executed in multiple trades.
The filing notes that the dispositions were carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, and company policy restricts changes to such plans after adoption. Following these transactions, Sherwin directly holds 15,860 shares of Neurocrine Biosciences common stock, and the exercised options reported here no longer remain outstanding.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia reported a charitable stock gift. On June 5, 2026, Onyia transferred 2,441 shares of common stock as a bona fide gift, with no price reported and no value received. Following the gift, Onyia directly holds 23,405 common shares. The filing notes this was not a market transaction, so it does not reflect open-market buying or selling activity.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk sold 1,250 shares of common stock in an open-market transaction on June 4, 2026 at a weighted average price of about $168.06 per share. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on September 15, 2025, and Norwalk now directly holds 2,838 shares.
Neurocrine Biosciences’ Chief Human Resources Officer Julie Cooke reported a mix of option exercise and share sales in company common stock. On June 2, 2026, she exercised 24,965 non-qualified stock options at an exercise price of $81.49 per share, converting them into common shares. The filing shows her holding 59,311 common shares directly after this exercise.
That same day, she executed a series of open-market sales totaling 36,937 common shares at weighted average prices ranging from the mid‑$154 to high‑$158 area, with specific ranges from $154.20 to $158.91. A footnote states these dispositions were carried out by a broker under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 3, 2026. The filing also notes that 20,334 of the reported shares are held by the Cooke Family Trust of 2004, over which Cooke has voting and investment power.
Neurocrine Biosciences’ Chief Medical Officer Sanjay Keswani reported routine equity-compensation activity. On June 2 2026, 3,212 restricted stock units (RSUs) vested, each converting into one share of common stock. To cover tax withholding on this vesting, 1,733 shares were withheld by the company at $154.84 per share; no shares were sold on the market.
The RSU grant, originally awarded on June 2 2025, vests over four years: 3,212 shares vested on June 2 2026 and further tranches of 3,212, 3,211 and 3,211 shares are scheduled to vest annually through June 2 2029, subject to award conditions.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised stock options and sold shares on June 1, 2026. He exercised options for 11,000 shares of common stock at an exercise price of $84.74 per share and sold 11,000 shares in an open-market transaction at a weighted average price of $160.2464 per share, with sale prices ranging from $160.00 to $160.66. After these transactions, he directly holds 25,846 shares of common stock and 13,268 non-qualified stock options. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, which the company’s policy does not allow him to amend after adoption.
NEUROCRINE BIOSCIENCES INC Chief Regulatory Officer Ingrid Delaet reported an option exercise combined with a routine share sale. On May 29, 2026, she exercised non-qualified stock options for 2,261 shares of common stock at an exercise price of $79.02 per share and sold 2,261 shares in an open-market transaction at $156.71 per share. After these transactions, she directly held 16,225 shares of common stock. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, which company policy does not allow her to amend or modify after adoption.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised options for 11,000 shares of common stock at $84.74 per share and, on the same day, sold 11,000 shares in open-market transactions at a weighted average price of $155.5332 per share.
The sale was carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026. Following these transactions, Onyia directly holds 25,846 shares of common stock and 24,268 non-qualified stock options.
NEUROCRINE BIOSCIENCES INC director Kevin Charles Gorman received a new stock option grant. He was awarded options on 5,248 shares of common stock at an exercise price of $155.83 per share. The options vest in 12 monthly installments beginning June 27, 2026 and expire on May 27, 2036.
POPS RICHARD F reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops received a grant of 2,567 Restricted Stock Units (RSUs). Each RSU represents one share of common stock upon vesting, and all 2,567 RSUs are scheduled to vest in full on May 27, 2027. Following this compensation award, Pops holds 2,567 RSUs directly.
NEUROCRINE BIOSCIENCES INC director Gary A. Lyons received new equity awards as part of his compensation. On May 27, 2026, he was granted non-qualified stock options for 2,624 shares of common stock at an exercise price of $155.83 per share, vesting in 12 monthly installments beginning June 27, 2026.
He also received 1,284 Restricted Stock Units, each representing one share of common stock upon vesting. These RSUs will vest in full on May 27, 2027. The filing shows these as direct holdings and reflects routine, compensation-related acquisitions rather than open-market buying or selling.
Mercier Johanna reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director Johanna Mercier received a grant of 2,567 restricted stock units (RSUs). Each RSU represents the right to receive one share of Neurocrine Biosciences common stock upon vesting. The RSUs will vest in full on May 27, 2027, and her direct holdings after this grant total 2,567 RSUs.
POON CHRISTINE A reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Christine A. Poon reported an equity compensation grant of 2,567 Restricted Stock Units. Each RSU represents one share of common stock upon vesting, and the entire award is scheduled to vest in full on May 27, 2027.
Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director Shalini Sharp received a grant of 2,567 restricted stock units (RSUs). Each RSU represents one share of common stock upon vesting, and the entire award will vest on May 27, 2027. This is a stock-based compensation grant, not an open-market share purchase or sale, and leaves her with 2,567 RSUs reported as directly held.
SHERWIN STEPHEN A reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin received a grant of 2,567 restricted stock units. These RSUs give him the right to receive an equal number of Neurocrine common shares when they vest. According to the award terms, the RSUs will vest in full on May 27, 2027, and he will then receive 2,567 shares if he remains eligible under the plan.
MORROW GEORGE J reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director George J. Morrow received a grant of 2,567 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of the company’s common stock upon vesting. The RSUs will vest in full on May 27, 2027, and the filing shows 2,567 derivative shares held directly after this award.
RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director William H. Rastetter received a grant of 2,567 Restricted Stock Units (RSUs). Each RSU represents one share of Neurocrine’s common stock when it vests. The award was made at no cash cost per unit and is held as a direct derivative position.
The RSUs will vest in full on May 27, 2027, meaning Rastetter will receive 2,567 common shares on that date if vesting conditions are satisfied. Following this grant, his reported derivative holdings from this award total 2,567 RSUs.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk received new equity awards. On May 27, 2026, Norwalk was granted 2,624 non-qualified stock options for common stock with an exercise price of $155.83 per share, expiring on May 27, 2036. These options vest in 12 monthly installments beginning on June 27, 2026.
Norwalk was also granted 1,284 Restricted Stock Units (RSUs), each representing the right to receive one share of common stock upon vesting. The RSUs will vest in full on May 27, 2027. These awards are compensation-related grants rather than open-market purchases or sales.
NEUROCRINE BIOSCIENCES INC Chief Corp. Affairs Officer David W. Boyer reported an open-market sale of 3,888 shares of common stock. The shares were sold at a weighted average price of $156.6418 per share in multiple trades between $155.81 and $157.62.
The transaction was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which the company’s policy does not allow him to amend after adoption. Following this sale, Boyer directly holds 7,799 shares, including 106 shares acquired through the company’s 2018 Employee Stock Purchase Plan.
NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at an exercise price of $0.00 per share. Following this compensation-related exercise, Sherwin directly holds 15,860 shares of Neurocrine common stock. The RSU award was granted on May 21, 2025 and is now fully vested, with no remaining units from this grant.
NEUROCRINE BIOSCIENCES INC director Shalini Sharp exercised restricted stock units into common stock. She acquired 1,659 shares of common stock from vested RSUs and did not sell any shares in this filing. Following the transaction, she directly holds 4,088 shares of common stock.
NEUROCRINE BIOSCIENCES INC director William H. Rastetter exercised restricted stock units into common shares. On May 21, 2026, he converted 3,318 Restricted Stock Units into 3,318 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related vesting event rather than a market purchase or sale.
After this transaction, Rastetter’s direct holdings increased to 43,678 common shares, which are held by the Rastetter Family Trust, where he has voting and investment power. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, and no remaining derivative position is reported in this filing.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at an exercise price of $0.00 per share. These RSUs were granted on May 21, 2025 and were fully vested. Following the transaction, Pops directly holds 37,798 shares of Neurocrine Biosciences common stock, reflecting a routine equity compensation event with no open-market buying or selling.
NEUROCRINE BIOSCIENCES INC director Christine A. Poon exercised restricted stock units into common shares. On May 21, 2026, she converted 3,318 fully vested Restricted Stock Units into an equal number of common shares at no cash cost, with no shares sold in this filing.
The RSUs were originally granted on May 21, 2025, with each unit representing one share upon vesting. Following the conversion, she directly holds 4,753 shares of Neurocrine Biosciences common stock.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk exercised restricted stock units into common shares. On 2026-05-21, Norwalk converted 1,659 Restricted Stock Units into 1,659 shares of Common Stock, a routine compensation-related equity acquisition with no reported share sales.
After the transaction, Norwalk directly holds 4,088 shares of Common Stock. The RSU award being exercised was granted on May 21, 2025 and was fully vested, meaning this filing reflects the settlement of previously awarded equity rather than new market purchases or sales.
NEUROCRINE BIOSCIENCES INC director George J. Morrow exercised restricted stock units into common shares. He converted 3,318 RSUs into 3,318 shares of common stock, increasing his direct common stock holdings to 10,386 shares. The RSU award, granted on May 21, 2025, was fully vested and each unit represented one share of common stock.
NEUROCRINE BIOSCIENCES INC director Johanna Mercier exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at a price of $0.00 per share. Following this derivative exercise, Mercier directly owns 6,853 shares of Neurocrine Biosciences common stock. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, making this a routine compensation-related transaction rather than an open-market purchase or sale.
Neurocrine Biosciences director Gary A. Lyons exercised fully vested restricted stock units, converting 1,659 RSUs into the same number of common shares. This reflects a derivative exercise at a stated price of $0.00 per unit, typical for equity compensation.
After the transaction, Lyons directly holds 122,141 common shares, including 116,158 shares held through the Gary A. Lyons Revocable Living Trust, over which he has voting and investment power. The filing shows no share sales, only the RSU conversion into stock.
Neurocrine Biosciences director Kevin Charles Gorman reported same-day option exercises and share sales in company stock. He exercised 205,088 Non-Qualified Stock Options at $43.24 per share, converting them into common shares, and sold 245,088 common shares at a weighted average price of $154.3318 per share in open-market transactions.
The sales were carried out by a broker under a Rule 10b5-1 trading plan adopted on February 17, 2026, which company policy prevents him from amending after adoption. Following these transactions, he holds 511,293 common shares, which are held by the Gorman and Blais Family Trust, where he has voting and investment power.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised 15,000 Non-Qualified Stock Options at a strike price of $47.89 per share and on the same day sold 15,000 common shares in open-market transactions. The weighted average sale price was $157.6507 per share, with individual trades ranging from $155.51 to $158.68. These sales were executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026. Following the transactions, Pops directly holds 34,480 shares of Neurocrine common stock. The options exercised were granted on May 20, 2016 and are scheduled to expire on May 20, 2026.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk sold 3,810 shares of common stock in an open-market transaction at a weighted average price of $155.0134 per share. The trades were executed by a broker at prices ranging from $155.00 to $155.0550.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which was adopted and made effective in advance and cannot be modified under issuer policy after adoption. Following this transaction, Norwalk directly holds 2,429 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences’ Chief Financial Officer Matt Abernethy reported a charitable stock gift. On March 4, 2026, he transferred 2,249 shares of Neurocrine Biosciences common stock as a bona fide gift, with no value received and no market transaction involved.
After this disposition, he directly holds 42,808 shares of common stock, which include 176 shares purchased on February 27, 2026 under the company’s 2018 Employee Stock Purchase Plan.